Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOCH-F/R Induction and Reduced-Intensity Allogeneic HSCT for Refractory/Relapsed Hematologic Malignancies
NCT00051311Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2003
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine and 2 more in hematologic malignancy, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease at 100 days and Number of Recipients Who Developed Chronic Graft Versus Host Disease at 100 days. Started Jan 2003; status: completed.
02
Drugs
fludarabinecyclophosphamideetoposidedoxorubicinvincristine
03
Conditions
hematologic malignancymyelodysplastic syndromes (MDS)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT00051311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051311.